Press Release Details

MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in the following upcoming investor conferences:

34th Annual ROTH Conference, Dana Point, California, U.S.

Maxim Group LLC 2022 Virtual Growth Conference

HC Wainwright Gene Therapy and Gene Editing Conference, virtual

8th Annual LSX World Congress, London, UK and virtual

Further information on these events may be found on the "News & Events" section of Genenta's Investor website at https://ir.genenta.com/news-events/events.

About Genenta Science 

Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a phase 1/2 clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which should induces a durable immune response not restricted to pre-selected tumor antigens nor type and aimed at reaching solid tumors, avoid systemic toxicity, some of the main unresolved challenges in immuno-oncology.

Source: Genenta Science